核苷(酸)类似物治疗慢加急性肝衰竭研究进展

王淼; 李用国

核苷(酸)类似物治疗慢加急性肝衰竭研究进展

王淼,
李用国

哈尔滨医科大学附属第一临床医学院感染科

详细信息

中图分类号: R575.3
计量
- 文章访问数: 143
- HTML全文浏览量: 6
- PDF下载量: 157
- 被引次数: 0
出版历程
- 出版日期: 2012-05-20

Antiviral therapy for patients with acute-on-chronic liver failure

摘要

摘要: 乙型肝炎是威胁全球的健康问题,每年约有60万人死于HBV感染所致的各种疾病,如肝炎、肝硬化和原发性肝癌等。乙型肝炎相关性慢加急性肝衰竭是我国肝衰竭主要类型,在治疗上除综合治疗外,是否进行抗病毒治疗是近年研究的热点。本文就该领域的研究现状作一综述。
- 肝炎,乙型 /
- 肝功能衰竭 /
- 抗病毒药 /
- 核苷酸类
Abstract: Hepatitis B virus is a major public health problem in the world.Every year, about 0.6 million people die of various diseases of HBV infection such as hepatitis, cirrhosis and hepatocellular carcinoma and so on.HBV related acute-on-chronic liver failure is the main type of liver failures in China.Whether or not antiviral therapy on the basis of comprehensive treatment has become a hot topic of recent research in the treatment of fulminant hepatitis B.This article summarizes recent advances in the treatment of HBV related liver failure with nucleoside analogues.
- hepatitis B /
- liver failure /
- antiviral agents /
- nucleotides

HTML全文

参考文献(31)

[1]World Health Organization Hepatitis B[DB/OL].World HealthOrganization Fact Sheet NO204 (Revised August 2008) .http://www.who.int/mediacentre/factsheets/fs204/enindex.html.

[2]Lu FM, Zhuang H.Management of hepatitis B in China[J].Chin Med J, 2009, 122 (1) :3-4.

[3]李兰娟.加强肝衰竭发病机制和人工肝治疗的研究[J].中华肝脏病杂志, 2009, 17 (5) :321-323.

[4] 刘晓燕, 胡瑾华, 王慧芬, 等.1977例急性、亚急性、慢加急性肝衰竭患者的病因与转归分[J].中华肝脏病杂志, 2008, 16 (10) :772-775.

[5]Zhang H, Wu LY, Zhang S, et al.Anti-hepatitis B virus Xprotein in sera is one of the markers of development of livercirrhosis and liver cancer mediated by HBV[J].J BiomedBiotechnol, 2009, 2009:289068.

[6]Xu Z, Ren X, Liu Y, et al.Association of hepatitis B virusmutations in basal core promoter and precore regions withseverity of liver disease:an investigation of 793 Chinese pa-tients with mild and severe chronic hepatitis B and acute-on-chronic liver failure[J].J Gastroenterol, 2011, 46 (3) :391-400.

[7]Ren X, Xu Z, Liu Y, et al.Hepatitis B virus genotype andbasal core promoter/precore mutations are associated withhepatitis B-related acute-on-chronic liver failure withoutpre-existing liver cirrhosis[J].J Viral Hepat, 2010, 17 (12) :887-895.

[8]Yang L, Ma S, Hu X, et al.Presence of valine at position 27of the hepatitis B virus core gene is associated with severeliver inflammation in Chinese patients[J].J Med Virol, 2011, 83 (2) :218-224.

[9]李兰娟, 王宇明.传染病学[M].北京:人民卫生出版社, 2008:65-79.

[10]叶一农, 高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22 (5) :276-279.

[11]Tsubota A, Arase Y, Suzuki Y, et al.Lamivudine monothera-py for spontaneous severe acute exacerbation of chronic hep-atitis B[J].J Gastroenterol Hepatol, 2005, 20 (3) :426-432.

[12]Yu JW, Sun LJ, Zhao YH, et al.The study of efficacy oflamivudine in patients with severe acute hepatitis B[J].DigDis Sci, 2010, 55 (3) :775-783.

[13]Cui YL, Yan F, Wang YB, et al.Nucleoside analogue canimprove the long-term prognos is of patients with hepatitisB virus infection associated acute on chronic liver failure[J].Dig Dis Sci, 2010, 55 (8) :2373-2380.

[14]Tillmann HL, Hadem J, Leifeld L, et al.Safety and efficacyof lamivudine in patients with severe acute or Fulminant hep-atitis B, amulticenter experience[J].J Viral Hepat, 2006, 13 (4) :256-263.

[15]张南, 夏杰, 邓国宏, 等.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].第三军医大学学报, 2008, 30 (1) :75-77.

[16]Wong VW, Wong GL, Tsang SW, et al.Long-term follow-up of lamivudine treatment in patients with severe acuteexacerbation of hepatitis Be antigen (HBeAg) -positive chro-nic hepatitis B[J].Antivir Ther, 2008, 13 (4) :571-579.

[17]Schiff E, Lai CL, Hadziyannis S, et al.Adefovir dipivoxil forwaitlisted and post-liver transplantation patients with lami-vudine-resistant hepatitis B:final long-term results[J].Liver Transpl, 2007, 13 (3) :349-360.

[18]Lo CM, Liu CL, Lau GK, et al.Liver transplantation for chro-nic hepatitis B with Lamivudine-resistant YMDD mutant u-sing add-on adefovir dipivoxil plus lamivudine[J].LiverTranspl, 2005, 11 (7) :807-813.

[19]Hosaka T, Suzuki F, Suzuki Y, et al.Adefovir dipivoxil fortreatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus[J].Intervirology, 2004, 47 (6) :362-369.

[20]吴广利, 侯敏, 吴立强, 等.拉米夫定相关性慢加急性肝衰竭8例[J].肝脏, 2008, 13 (40) :355.

[21]舒欣, 徐启桓, 陈旎, 等.HBeAg阴性乙型肝炎ACLF患者的临床特征及抗病毒治疗短期疗效[J].中华实验和临床病毒学杂志, 2008, 22 (6) :481-483.

[22]舒欣, 徐启桓, 陈旎, 等.恩替卡韦在乙型肝炎慢加急性肝功能衰竭中的应用[J].中华传染病杂志, 2009, 27 (5) :281-286.

[23]胡瑾华, 黄坤, 王慧芬, 等.乙型肝炎相关慢加急性肝衰竭190例生存分析[J].传染病信息, 2010, 23 (2) :83-85.

[24]Chen T, He Y, Liu X, et al.Nucleoside analogues improvethe short-term and long-term prognosis of patients withhepatitis B virus-related acute-on-chronic liver failure[J].Clin Exp Med, 2011 Oct 15.[Epub ahead of print]

[25]李芳, 陶晨, 杜建霞.恩替卡韦治疗慢性乙型重型肝炎的近期疗效观察[J].实用肝脏病杂志, 2008, 11 (6) :383-384.

[26]Chen J, Han JH, Liu C, et al.Short-term entecavir thera-py of chronic severe hepatitis B[J].Hepatobiliary PancreatDis Int, 2009, 8 (3) :261-266.

[27]Wong VW, Wong GL, Yiu KK, et al.Entecavir treatment inpatients with severe acute exacerbation of chronic hepatitis B[J].J Hepatol, 2011, 54 (2) :236-242.

[28]郑玉山, 孙凤兰, 刘现红.替比夫定与恩替卡韦治疗慢加急性肝衰竭的疗效分析[J].临床肝胆病杂志, 2011, 27 (6) :641-642, 646.

[29]Heathcote EJ, Marcellin P, Buti M, et al.Three-year effi-cacy and safety of tenofovir disoproxil fumarate treatment forchronic hepatitis B[J].Gastroenterology, 2011, 140 (1) :132-143.

[30]Taltavull TC, Chahri N, Verdura B, et al.Successful treat-ment with tenofovir in a child C cirrhotic patient with lamivu-dine-resistant hepatitis B virus awaiting liver transplanta-tion.Post-transplant results[J].Transpl Int, 2005, 18 (1) :879-883.

[31]Garg H, Sarin SK, Kumar M, et al.Tenofovir improves theoutcome in patients with spontaneous reactivation of hepati-tis B presenting as acute-on-chronic liver failure[J].Hep-atology, 2011, 53 (3) :774-780. (本文编辑:刘晓红

施引文献

资源附件(0)

访问统计